HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
NTLA
Intellia Therapeutics Inc
Healthcare Biotechnology · Massachusetts, USA · Reports in usd
Market Cap: $1.56B
Market Cap
$1.56B
Enterprise Val
$1.20B
P/E Ratio
-3.78
P/B Ratio
2.33
Trailing PEG (1Y)
0.11
As Of
Apr 29, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$671.4M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-56.63%
Return on Assets-45.20%
Current Ratio5.08
Debt/Equity0.14
LT Debt/Equity0.10
Revenue Per Share0.20

Income Statement

Dec 31, 2025
Revenue$23.0M
Cost of Revenue$0.00
Gross Profit$23.0M
R&D$88.7M
SG&A$33.1M
Operating Expenses$121.7M
Operating Income-$98.7M
Interest Expense$0.00
Tax Expense$0.00
Net Income-$95.8M
EPS (Basic)$-0.82
EPS (Diluted)$-0.82
EBIT-$95.8M
EBITDA-$89.8M
Consolidated Income-$95.8M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$155.5M
Accounts Receivable$9.5M
Inventory$0.00
Current Assets$527.7M
LT Investments$190.8M
Property, Plant & Equipment$123.6M
Intangibles$0.00
Non-Current Assets$314.4M
Total Assets$842.1M
Accounts Payable$20.3M
Current Debt$26.5M
Current Liabilities$103.9M
LT Debt$66.8M
Non-Current Liabilities$66.8M
Total Liabilities$170.7M
Total Debt$93.3M
Retained Earnings-$2.59B
Shareholder Equity$671.4M
Shares Outstanding115,829,926

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$69.3M
Investing Cash Flow$27.5M
Financing Cash Flow$2.0M
CapEx-$126.0K
Free Cash Flow-$69.4M
Depreciation & Amort.$6.0M
Stock-Based Comp$16.7M
Acquisitions / Disposals$0.00
Investment Activity$27.7M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$625.0K
Dividends Paid$0.00
Net Change in Cash-$39.8M
Data cached · Meta live · Daily live · Statements live · TTL 24h